Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients

• Published in: Journal of allergy and clinical immunology 2013-03, Vol.131 (3), p.909-911.e5
• Main Authors: Farkas, Henriette, MD, PhD, DSc, Csuka, Dorottya, MSc, Zotter, Zsuzsanna, MD, Szabó, Erika, MD, Czaller, Ibolya, MD, Varga, Lilian, PhD, Fejes, János, MD, Füst, George, PhD, DSc, Harmat, George, MD, PhD
• Format: Article
• Language: English
• Subjects: Abdomen; Adolescent; Age; Allergy and Immunology; Angioedema; Angioedemas, Hereditary - drug therapy; Antibodies - blood; Child; Children & youth; Complement C1 Inhibitor Protein - administration & dosage; Complement C1 Inhibitor Protein - immunology; Female; Humans; Male; Pediatrics; Recombinant Proteins - administration & dosage; Treatment Outcome
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2012.08.036

Only limited original data exist on the treatment of attacks in the pediatric population with the pdC1-INH concentrate (Berinert; CSL Behring, Marburg, Germany), which is the sole drug licensed for use in patients of all ages.3,5,6 Original, retrospective, or prospective studies, conducted on large patient populations, have been published by 2 groups.7,8 The aim of this study was to analyze prospectively the efficacy and safety of the pdC1-INH concentrate (Berinert) used in the treatment of attacks in pediatric patients with HAE. [...]we have been recommending this dose since 2010.9 Another important finding from our study is that there were no treatment-related adverse events with the pdC1-INH concentrate either during use at home or in the hospital setting.